Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it entered into a private placement worth $5 million. Dublin, Ohio-based Navidea’s agreement comes with its largest shareholder, John K. Scott, Jr., for the purchase of $5 million in newly-designated Series E redeemable convertible preferred stock, according to a news release. Over the course of the next 18 months, the […]
Funding Roundup
DTx Pharma completes $100M Series B
RNA-based therapeutic developer DTx Pharma announced today that it completed a $100 million Series B financing round. RA Capital Management led the financing round with participation from new investors Access Biotechnology, Surveyor Capital (a Citadel company), Cormorant Asset Management, Janus Henderson Investors, and Logos Capital. Additionally, existing investors Friedman Bioventure Fund, Eli Lilly, Viva BioInnovator […]
BriaCell Therapeutics closes $25M offering
BriaCell Therapeutics (NSDQ:BCTX) announced today that it closed an underwritten public offering worth $25 million. Berkeley, Calif.-based BriaCell offered more than 4.85 million common units comprised of one share of common stock and one warrant to purchase one share of common stock priced at $4.25 per unit, according to a news release. Additionally, the offering […]
AmacaThera raises $10.3M in oversubscribed Series A
AmacaThera announced today that it completed an oversubscribed $10.3 million Series A financing round. Lumira Ventures led the Series A funding, with existing investors Viva BioInnovator and Sprout BioVentures contributing as well. New investors BDC Capital Women in Technology Venture Fund, Inveready, MBX Capital, CR Capital Management, StandUp Ventures and MaRS IAF participated, too, according […]
Evox Therapeutics completes $95.4M Series C
Evox Therapeutics announced today that it raised $95.4 million (£69.2 million) in a Series C financing round. Oxford, England-based Evox’s financing was significantly oversubscribed with high demand from both existing and new investors, according to a news release. Redmile Group led the financing while being joined by new investors OrbiMed and Invus. OrbiMed partner Chau […]
Senseonics announces $50M from stock offering
Senseonics (NYSE:SENS) announced that it entered into securities purchase agreements worth gross proceeds of approximately $50 million. Germantown, Md.-based Senseonics’ purchase agreements are with several healthcare-focused investors, as well as other institutional investors, according to a news release. Investors have agreed to purchase 40 million shares of the implantable continuous glucose monitor maker’s common stock at […]
Pear Therapeutics closes $80M Series D
Substance use and opioid use treatment developer Pear Therapeutics announced that it closed an $80 million Series D financing round. Existing investors Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, CrimsoNox and EDBI contributed, as did new investors Forth Management, Pilot House, Sarissa Capital, Shanda Group, and QUAD Investment Management, according to a news […]
Brooklyn spending $500K on BioBAT research and manufacturing space
SUNY Downstate Health Sciences University announced that it received a $500,000 capital fund grant from Brooklyn to construct a research space. Brooklyn Borough President Eric Adams awarded the grant to SUNY to construct a state-of-the-art biotechnology research and manufacturing space at BioBAT, a nonprofit organization seeking to grow the biotechnology industry in New York City. […]
Baxter lands major DoD contract
The U.S. Defense Dept. (DoD) announced that it awarded Baxter (NYSE:BAX) $40 million for its infusion pumps and accessories. Baxter’s contract includes a maximum $40 million fixed-price award with economic-price-adjustment and indefinite-delivery/indefinite-quantity for its infusion pumps and accessories. The competitive acquisition had 105 offers received. The five-year contract has no option periods with the location being […]
HHS gives Vaxxas $22M to support vaccine patch tech
Vaxxas announced today that it has received a $22 million award from the Biomedical Advanced Research and Development Authority (BARDA) at U.S. HHS to support a clinical study involving the company’s vaccine-delivery patch. The money will mostly pay for a Phase 1 clinical study in which Vaxxas’ high-density micro-array patch (HD-MAP) delivering pandemic influenza vaccine […]